Evommune (EVMN) Corporate presentation summary

Addressing chronic inflammation and unmet needs

• Chronic inflammation contributes to 3 out of 5 deaths globally and costs at least $90B annually.

• Current therapies for chronic inflammation often lack efficacy and safety for most patients.

• Focus on immune-mediated diseases with significant gaps in care and economic viability.

Pipeline and clinical programs

• EVO756 is an oral MRGPRX2 antagonist targeting mast cell-mediated diseases and neuroinflammation, advancing in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD).

• EVO301 is a long-acting IL-18BP fusion protein for AD, with potential for broader immune modulation.

• Multiple preclinical programs are progressing toward clinical proof-of-concept.

EVO756 clinical data and development

• Phase 1 and 2 trials show EVO756 is well-tolerated, with clear target engagement and early clinical responses in urticaria.

• At 4 weeks, 30% of patients achieved complete response in FricTest, with potential for increased response over longer dosing.

• Safety profile is favorable, with no serious adverse events or discontinuations due to adverse events.

• Phase 2b trials in CSU and AD are underway, with topline data expected in 2026.